Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Heudobler, D., Borchmann, P., Bokemeyer, C., Klobuch, S., Smit, E., Mueller, F., Desuki, A., Lueke, F., Wiegert, E., Flemmig, C., Schulz-Eying, C., Rengstl, B., Preussner, L., Tuereci, O. and Sahin, U. (2022). BNT211-01: A phase I trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours. Ann. Oncol., 33 (7). S. S1404 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Thunnissen, E., Lissenberg-Witte, B., Van den Heuvel, M., Monkhorst, K., Skov, B., Sorensen, J., Mellemgaard, A., Dingemans, A., Speel, E., De langen, J., Hashemi, S., Bahce, I., Van Der Drift, M., Buettner, R., Salomon, M. Looijen, Gosney, J., Postmus, P. E., Samii, S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Oz, B., Akyurek, N., Wolf, J., Bubendorf, L., Hiemstra, A., Duin, S., Marondel, L., Timens, W., Schuuring, E., Pauwels, P. and Smit, E. (2018). Crizotinib-Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative. J. Thorac. Oncol., 13 (10). S. S452 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

This list was generated on Thu Mar 28 09:14:46 2024 CET.